SOST and Miyoshi myopathy: At the same time, sclerostin, a secreted glycoprotein from the bone tissue, can be targeted therapeutically by Romosozumab, an anti-sclerostin antibody, which represents a potential new therapeutic strategy in MM bone disease (102, 103).